Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Wael Harb, Mansoor N. Saleh, MD, Kyriakos P Papadopoulos, MD, Feng Chai, MD, Maria Larmar, Giovanni Abbadessa, MD, Brian Schwartz, MD, Anthony Tolcher, MD

Blood (2015) 126 (23): 5116.

https://doi.org/10.1182/blood.V126.23.5116.5116

Published: 2015

Journal Articles

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Howard Liebman, MD, James B Bussel, MD, Mansoor N Saleh, MD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2013) 122 (21): 1080.

https://doi.org/10.1182/blood.V122.21.1080.1080

Published: 2013

Journal Articles

Update On The Safety and Efficacy Of EXTENDed Treatment With Eltrombopag (EPAG) In Adults With Chronic Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Mansoor N. Saleh, MD, Raymond S.M. Wong, Paul Burgess, Kalpana Bakshi, BS, MS, Geoffrey W. Chan, MD, Christine K. Bailey, PhD

Blood (2013) 122 (21): 2315.

https://doi.org/10.1182/blood.V122.21.2315.2315

Published: 2013

Journal Articles

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Kavita R Sail, MS, PhD, Lei Chen, MD, PhD, James Jackson, PharmD, MPH, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Tamara Ibison, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 3179.

https://doi.org/10.1182/blood.V120.21.3179.3179

Published: 2012

Journal Articles

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

James Jackson, PharmD, MPH, Lei Chen, MD, PhD, Kavita R Sail, MS, PhD, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Joyce Sharpe, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 2066.

https://doi.org/10.1182/blood.V120.21.2066.2066

Published: 2012

Journal Articles

Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.

Mansoor N Saleh, MD, Gregory Cheng, James B Bussel, MD, Paul Burgess, Kalpana Bakshi, BS, MS, Andres Brainsky, MD, Christine K Bailey, PhD

Blood (2012) 120 (21): 2198.

https://doi.org/10.1182/blood.V120.21.2198.2198

Published: 2012

Journal Articles

Dynamics of Improvement in Health-Related Quality of Life (HRQoL) with Long-Term Eltrombopag Treatment in Adults with Chronic Immune Thrombocytopenia (ITP) in EXTEND.

Kelly M Grotzinger, James B Bussel, MD, Mansoor N Saleh, MD, Christine Bieri, MBA, Yuliya Orlova, Andres Brainsky, MD

Blood (2012) 120 (21): 2199.

https://doi.org/10.1182/blood.V120.21.2199.2199

Published: 2012

Journal Articles

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Howard A. Liebman, MA, MD, Mansoor N Saleh, MD, James B. Bussel, MD, O George Negrea, MD, Heather Horne, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 622.

https://doi.org/10.1182/blood.V120.21.622.622

Published: 2012

Journal Articles

Safety and Efficacy of Extended Treatment with Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2011,

Mansoor N Saleh, MD, Gregory Cheng, MD, PhD, James B Bussel, MD, Paul Burgess, Lisa Marcello, BA, MS, Christine K Bailey, PhD, Andres Brainsky, MD

Blood (2011) 118 (21): 3296.

https://doi.org/10.1182/blood.V118.21.3296.3296

Published: 2011

Journal Articles

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Howard A Liebman, MD, Mansoor N Saleh, MD, James B Bussel, MD, Zale P Bernstein, MD, O George Negrea, MD, Anthony C Onyegbula, DO, Charles M Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2011) 118 (21): 3302.

https://doi.org/10.1182/blood.V118.21.3302.3302

Published: 2011

Journal Articles

EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010

Mansoor N. Saleh, MD, Gregory Cheng, MD, PhD, James B. Bussel, MD, Huiping Sun, Bhabita Mayer, MSc, Christine Bailey, PhD, Andres Brainsky, MD

Blood (2010) 116 (21): 67.

https://doi.org/10.1182/blood.V116.21.67.67

Published: 2010

Journal Articles

Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Gregory Cheng, MD, PhD, Mansoor N. Saleh, MD, Bhabita Mayer, MSc, Sandra Y. Vasey, MS, Andres Brainsky, MD

Blood (2010) 116 (21): 70.

https://doi.org/10.1182/blood.V116.21.70.70

Published: 2010

Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose

Blood (2010) 116 (21): 3960.

https://doi.org/10.1182/blood.V116.21.3960.3960

Published: 2010

Journal Articles

Thromboembolic Events Observed in Eltrombopag Clinical Trials in Chronic Immune Thrombocytopenic Purpura.

James B. Bussel, MD, Gregory Cheng, Mansoor N. Saleh, MD, Sandra Vasey, Manuel Aivado, Andres Brainsky

Blood (2009) 114 (22): 2423.

https://doi.org/10.1182/blood.V114.22.2423.2423

Published: 2009

Journal Articles

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Mansoor N Saleh, MD, Howard Liebman, MD, Zale P. Bernstein, MD, O. George Negrea, MD, James B. Bussel, MD, Anthony C. Onyegbula, DO, Charles M Farber, MD, PhD, Rashid Abassi, MD, Thomas M. Cosgriff, MD, Kenneth Pennington, MD, Heather Horne, Nick Teoh, PhD, Asraf Gomaa, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2009) 114 (22): 1322.

https://doi.org/10.1182/blood.V114.22.1322.1322

Published: 2009

Journal Articles

Results of Bone Marrow Examinations in Patients with Chronic Immune Thrombocytopenic Purpura Treated with Eltrombopag.

Mansoor N. Saleh, MD, James B. Bussel, MD, Oliver Meyer, Henrik Frederiksen, Diane Johnni, Manuel Aivado, Andres Brainsky

Blood (2009) 114 (22): 1326.

https://doi.org/10.1182/blood.V114.22.1326.1326

Published: 2009

Journal Articles

Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.

Mansoor N. Saleh, MD, James B. Bussel, MD, Gregory Cheng, Balkis Meddeb, Bhabita Mayer, Christine Bailey, Manuel Aivado

Blood (2009) 114 (22): 682.

https://doi.org/10.1182/blood.V114.22.682.682

Published: 2009

Journal Articles

Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study.

Howard A. Liebman, MA, MD, Mansoor N. Saleh, MD, Rashid Abassi, MD, Thomas M. Cosgriff, MD, Nick Teoh, PhD, Matthew J Leoni, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2008) 112 (11): 3412.

https://doi.org/10.1182/blood.V112.11.3412.3412

Published: 2008

Journal Articles

Pharmacoeconomic Evaluation of Hypomethylating Agents Used for the Treatment of MDS

Bruce Feinberg, James Gilmore, Sally Haislip, Carlos M. Franco, MD, Tom Gondesen, Mansoor N. Saleh, MD

Blood (2008) 112 (11): 2380.

https://doi.org/10.1182/blood.V112.11.2380.2380

Published: 2008

Journal Articles

Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

James B. Bussel, MD, Gregory Cheng, MD, Lidia Kovaleva, MD, Mansoor N. Saleh, MD, Balkis Meddeb, MD, Bhabita Mayer, PhD, J. Lee Fraser, PhD, Manuel Aivado, MD

Blood (2007) 110 (11): 566.

https://doi.org/10.1182/blood.V110.11.566.566

Published: 2007

NARROW

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Update On The Safety and Efficacy Of EXTENDed Treatment With Eltrombopag (EPAG) In Adults With Chronic Immune Thrombocytopenia (ITP)

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.

Dynamics of Improvement in Health-Related Quality of Life (HRQoL) with Long-Term Eltrombopag Treatment in Adults with Chronic Immune Thrombocytopenia (ITP) in EXTEND.

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Safety and Efficacy of Extended Treatment with Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2011,

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010

Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP)

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Thromboembolic Events Observed in Eltrombopag Clinical Trials in Chronic Immune Thrombocytopenic Purpura.

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Results of Bone Marrow Examinations in Patients with Chronic Immune Thrombocytopenic Purpura Treated with Eltrombopag.

Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.

Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study.

Pharmacoeconomic Evaluation of Hypomethylating Agents Used for the Treatment of MDS

Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only